Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 111 of 1,261
  1. US 12011425

    Hepatitis B antiviral agents

    Enanta Pharmaceuticals, Inc. Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  2. US 12012467

    Small molecule DCN1 inhibitors and therapeutic methods using the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  3. US 12012459

    OX40-binding polypeptides and uses thereof

    Inhibrx, Inc. Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  4. US 12012460

    Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

    Dyne Therapeutics, Inc. Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  5. US 12012444

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  6. US 12012445

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  7. US 12012454

    Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same

    China Medical University Hospital Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  8. US 12012455

    Human monoclonal antibodies specific for FLT3 and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  9. US 12012436

    Methods of treating mitochondrial disorders

    The Regents of the University of California Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  10. US 12011619

    Low intensity focused ultrasound for treating cancer and metastasis

    Montefiore Medical Center Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  11. US 12011502

    Compositions and methods of administering baclofen

    AMNEAL PHARMACEUTICALS LLC Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  12. US 12012419

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  13. US 12011437

    Roflumilast formulations with an improved pharmacokinetic profile

    ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  14. US 12012395

    Pyridazinone compounds and uses thereof

    EDGEWISE THERAPEUTICS, INC. Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  15. US 12012463

    High affinity monoclonal antibodies targeting glypican-2 and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  16. US 12011450

    Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  17. US 12012468

    Cyclic polypeptides for PCSK9 inhibition

    RA PHARMACEUTICALS, INC. Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  18. US 12013406

    Methods of detecting anti-folic acid antibodies and uses thereof

    The Board of Regents of the University of Texas System Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  19. US 12010979

    Non-human animals comprising a humanized TTR locus and methods of use

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  20. US 12012384

    Dextrorphan prodrugs and processes for making and using them

    Zevra Therapeutics, Inc. Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  21. US 12011390

    Lacrimal drug delivery device

    The Regents of the University of Colorado, a Body Corporate Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  22. US 12011488

    Methods of treating mitochondrial disorders

    The Regents of the University of California Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  23. US 12012437

    Methods of treating mitochondrial disorders

    The Regents of the University of California Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted
  24. US 12012438

    Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use

    The United States of America, as represented by the Secretary, Health and Human Services Β· Granted Jun 18, 2024 Β· Expires Jun 13, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.